NeuroSense Therapeutics has reported promising results from their NST002 Phase IIa clinical study. Patients at the Tel-Aviv Sourasky Medical Center received 9 months of treatment with PrimeC, after which positive trends in patients’ respiratory and overall function were observed, similar to the 6-month analysis results. In January 2021, the study will be concluded after 12 months of treatment.
All participating patients have requested to continue with PrimeC treatment after the clinical study is completed.
